Multiple Myeloma Market Size, Industry Trends Report | 2031
Multiple Myeloma Market Size, Industry Trends Report | 2031
Segments - Multiple Myeloma Market by Types (Active Multiple Myeloma and Smoldering Multiple Myeloma), Diagnosis (Urine Test, Blood Test, Bone Marrow Test, Imaging Test, specialized Test, and Others), Treatments (Radiation Therapy, Medication, Stem Cell Transplant, and Others), Dosage Forms (Tablets, Injections, Capsules, and Others), Routes of Administration (Parenteral, Oral, and Others), Distribution Channels (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, and Others), End-users (Specialty Clinics, Homecare, Hospitals, and Others), and Regions (Asia Pacific, North America, Latin America, Europe and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2022 – 2030
Upcoming
| Report ID :HC-4206
| 4.7 Rating
| 84 Reviews
| 180 Pages
| Format :
Report Description
The global multiple myeloma market size was valued at around USD 19.5 billion in 2021 and is estimated to reach USD 30.1 billion by 2030, expanding at a CAGR of around 4.1% during the forecast period, 2022 – 2030. The growth of the market is attributed to the higher amount of diagnosis of the disease and increasing sophistication of treatments.
Multiple myeloma is a type of cancer that forms in white blood cells called plasma cells. Healthy plasma cells make antibodies, which recognize and attack germs and fight infections. In multiple myeloma, cancerous plasma cells amass in the bone marrow, which force out healthy blood cells. These cancerous cells produce unusual proteins that cause health complications. Symptoms of multiple myeloma do not occur in early stages of the disease. Signs and symptoms usually occur in later stages of disease such as bone pain, nausea, loss of appetite, fatigue, constipation, weight loss, excessive thirst, weakness in legs, and others. Although researchers are not sure regarding the exact causes of multiple myeloma, some protentional causes include genetic mutation, inflammatory diseases, obesity, and exposure to radiation and chemicals. Multiple myeloma is considered treatable; however, it is considered as incurable. Healthcare providers provide some treatments to control and manage the symptoms, such as pain medications, steroids, antibiotics, stem cell transplants, and radiation therapies.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of multiple myeloma is expected to drive the market during the forecast period.
- Growing investments in technological advancements in the medical field boosts the market.
- Surging number of drug launches and approvals is estimated to fuel the market in the coming years.
- Rising cost of treatments is anticipated to hamper the growth of the market during the forecast period.
- Increasing number of research & development activities regarding multiple myeloma offers growth opportunities to the key market players.
Scope of the Report
The report on the global multiple myeloma market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Multiple Myeloma Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2021 |
|
Historic Data |
2019–2020 |
|
Forecast Period |
2022–2030 |
|
Segmentation |
Types (Active Multiple Myeloma and Smoldering Multiple Myeloma), Diagnosis (Urine Test, Blood Test, Bone Marrow Test, Imaging Test, Specialized Test, and Others), Treatments (Radiation Therapy, Medication, Stem Cell Transplant, and Others), Dosage Forms (Tablets, Injections, Capsules, and Others), Routes of Administration (Parenteral, Oral, and Others), Distribution Channels (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, and Others), and End-users (Specialty Clinics, Homecare, Hospitals, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
AbbVie, Inc.; Gland Pharma Limited; F. Hoffmann-La Roche Ltd; Sanofi; Johnson & Johnson Services, Inc.; Pfizer, Inc.; Novartis International AG; Eagle Pharmaceuticals, Inc.; GSK Group of Companies; Teva Pharmaceuticals Industries, Ltd.; Fresenius Kabi AG; Bristol-Myers Squibb Company; Alvogen; Hikma Pharmaceuticals PLC; Bayer AG; Cipla, Inc.; Lupin Limites; Sun Pharmaceuticals Industries, Ltd.; and Others |
Market Segment Insights
Smoldering multiple myeloma segment drives the market
Based on Types, the global multiple myeloma market is divided into Active Multiple Myeloma and Smoldering Multiple Myeloma. The smoldering multiple myeloma market is expected to boost the market during the forecast period, as it is an asymptomatic disease with no cure for it available. The active multiple myeloma market is anticipated to expand during in the coming years, as there are treatments to cure the cancer.
Specialized test segment boosts the market
In terms of diagnosis, the market is segmented into urine test, blood test, bone marrow test, imaging test, specialized test, and others. The specialized test segment is projected to drive the market during the forecast period, as specialized tests such as fluorescence in situ hybridization (FISH) analyze multiple myeloma cells to identify gene mutations for precise results. The blood test and bone marrow test segments are estimated to spur the market in the coming years, as these tests are easily available and commonly used to diagnose multiple myeloma.
Radiation therapy segment dominates the market
Based on treatments, the market is divided into radiation therapy, medication, stem cell transplant, and others. The radiation therapy segment is estimated to expand at a rapid pace, as it effectively treats multiple myeloma in specific situation and lower complications from bone disease.
Tablets segment holds a key market share
On the basis of dosage forms, the market is segregated into tablets, injections, capsules, and others. The tablets segment is estimated to fuel the market during the forecast period, as tablets are easily available and easy to consume. The capsules segment is anticipated to expand during the forecast period, due to its availability and easy usage.
Oral segment fuels the market
In terms of routes of administration, the market is divided into parenteral, oral, and others. The oral segment is expected to boost the market during the forecast period, as oral drugs prevent further bone damage and they are easy to consume.
Hospital pharmacy segment holds a key market share
Based on distribution channels, the market is segmented into retail pharmacy, hospital pharmacy, online pharmacy, and others. The hospital pharmacy segment is expected to drive the market during the forecast period, as availability of regularly prescribed and administered drugs in hospital settings in hospital pharmacracies. Higher administration of intravenous therapeutics aid in the expansion of the hospital pharmacy segment. The online pharmacy segment is anticipated to expand rapidly during the projected period, due to its ease and convenience in filling up the prescriptions.
Specialty clinics segment boosts the market
On the basis of end-users, the market segregated into specialty clinics, homecare, hospitals, and others. The specialty clinics segment is projected to boost the market during the forecast period, due to availability of doctors specializing in treating blood and bone marrow disorders or doctors specializing in treating cancer in such clinics.
North America dominates the market
In terms of regions, the market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to register a significant CAGR during the forecast years, due to growing prevalence of blood cancer and rising geriatric population in the region. Changing lifestyles and increasing demand for biologic therapies in North America is propels the market in the region. The market in Asia Pacific is anticipated to expand during the forecast period, owing increasing penetration of novel cancer drugs, growing obesity, and rising healthcare expenditure in the region.
Segments
The global multiple myeloma- market has been segmented on the basis ofTypes
- Active Multiple Myeloma
- Smoldering Multiple Myeloma
- Urine Test
- Blood Test,
- Bone Marrow Test
- Imaging Test
- Specialized Test
- Others
- Radiation Therapy
- Medication
- Stem Cell Transplant
- Others
- Tablets
- Injections
- Capsules
- Others
- Parenteral
- Oral
- Others
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Others
- Specialty Clinics
- Homecare
- Hospitals
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- AbbVie, Inc.
- Gland Pharma Limited
- F. Hoffmann-La Roche Ltd
- Sanofi
- Johnson & Johnson Services, Inc.
- Pfizer, Inc.
- Novartis International AG
- Eagle Pharmaceuticals, Inc.
- GSK Group of Companies
- Teva Pharmaceuticals Industries, Ltd.
- Fresenius Kabi AG
- Bristol-Myers Squibb Company
- Alvogen
- Hikma Pharmaceuticals PLC
- Bayer AG
- Cipla, Inc.
- Lupin Limited
- Sun Pharmaceuticals Industries, Ltd.
- Others
Competitive Landscape
The global multiple myeloma market is highly competitive with the presence of key players such as AbbVie, Inc.; Gland Pharma Limited; F. Hoffmann-La Roche Ltd; Sanofi; Johnson & Johnson Services, Inc.; Pfizer, Inc.; Novartis International AG; Eagle Pharmaceuticals, Inc.; GSK Group of Companies; Teva Pharmaceuticals Industries, Ltd.; Fresenius Kabi AG; Bristol-Myers Squibb Company; Alvogen; Hikma Pharmaceuticals PLC; Bayer AG; Cipla, Inc.; Lupin Limited; Sun Pharmaceuticals Industries, Ltd.; and others, who use strategies such as mergers, acquisitions, product launches, collaborations, and partnerships to strengthen their hold on the market. For example, May 2022, Gland Pharma Limited launched Bortezomib for injections to treat multiple myeloma. In April 2022, Sanofi launched Diversity, Equity, & Inclusion Board (DE&I), which is a first-of-a-kind board to feature outside advisors.
Frequently Asked Questions
AbbVie, Inc.; Gland Pharma Limited; F. Hoffmann-La Roche Ltd; Sanofi; Johnson & Johnson Services, Inc.; Pfizer, Inc.; Novartis International AG; Eagle Pharmaceuticals, Inc.; GSK Group of Companies; and Teva Pharmaceuticals Industries, Ltd. are some of the key players in the market.
North America dominates the global multiple myeloma market.
Multiple myeloma is a type of cancer that forms in white blood cells called plasma cells.
The global multiple myeloma market size was valued at around USD 19.5 billion in 2021.
The market is estimated to register CAGR of around 4.1% during the forecast period.
Signs and symptoms usually occur in later stages of disease such as bone pain, nausea, loss of appetite, fatigue, constipation, weight loss, excessive thirst, weakness in legs, and others.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Multiple Myeloma Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Multiple Myeloma Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Multiple Myeloma Market - Supply Chain
4.5. Global Multiple Myeloma Market Forecast
4.5.1. Multiple Myeloma Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Multiple Myeloma Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Multiple Myeloma Market Absolute $ Opportunity
5. Global Multiple Myeloma Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Multiple Myeloma Market Size and Volume Forecast by Types
5.3.1. Active Multiple Myeloma
5.3.2. Smoldering Multiple Myeloma
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Multiple Myeloma Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Multiple Myeloma Market Size and Volume Forecast by End Users
6.3.1. Specialty Clinics
6.3.2. Homecare
6.3.3. Hospitals
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Multiple Myeloma Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Multiple Myeloma Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Multiple Myeloma Demand Share Forecast, 2019-2026
8. North America Multiple Myeloma Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Multiple Myeloma Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Multiple Myeloma Market Size and Volume Forecast by Types
8.4.1. Active Multiple Myeloma
8.4.2. Smoldering Multiple Myeloma
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Multiple Myeloma Market Size and Volume Forecast by End Users
8.7.1. Specialty Clinics
8.7.2. Homecare
8.7.3. Hospitals
8.7.4. Others
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Multiple Myeloma Demand Share Forecast, 2019-2026
9. Latin America Multiple Myeloma Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Multiple Myeloma Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Multiple Myeloma Market Size and Volume Forecast by Types
9.4.1. Active Multiple Myeloma
9.4.2. Smoldering Multiple Myeloma
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Multiple Myeloma Market Size and Volume Forecast by End Users
9.7.1. Specialty Clinics
9.7.2. Homecare
9.7.3. Hospitals
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Multiple Myeloma Demand Share Forecast, 2019-2026
10. Europe Multiple Myeloma Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Multiple Myeloma Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Multiple Myeloma Market Size and Volume Forecast by Types
10.4.1. Active Multiple Myeloma
10.4.2. Smoldering Multiple Myeloma
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Multiple Myeloma Market Size and Volume Forecast by End Users
10.7.1. Specialty Clinics
10.7.2. Homecare
10.7.3. Hospitals
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Multiple Myeloma Demand Share Forecast, 2019-2026
11. Asia Pacific Multiple Myeloma Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Multiple Myeloma Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Multiple Myeloma Market Size and Volume Forecast by Types
11.4.1. Active Multiple Myeloma
11.4.2. Smoldering Multiple Myeloma
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Multiple Myeloma Market Size and Volume Forecast by End Users
11.7.1. Specialty Clinics
11.7.2. Homecare
11.7.3. Hospitals
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Multiple Myeloma Demand Share Forecast, 2019-2026
12. Middle East & Africa Multiple Myeloma Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Multiple Myeloma Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Multiple Myeloma Market Size and Volume Forecast by Types
12.4.1. Active Multiple Myeloma
12.4.2. Smoldering Multiple Myeloma
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Multiple Myeloma Market Size and Volume Forecast by End Users
12.7.1. Specialty Clinics
12.7.2. Homecare
12.7.3. Hospitals
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Multiple Myeloma Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Multiple Myeloma Market: Market Share Analysis
13.2. Multiple Myeloma Distributors and Customers
13.3. Multiple Myeloma Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. AbbVie, Inc.
13.4.2. Gland Pharma Limited
13.4.3. F. Hoffmann-La Roche Ltd
13.4.4. Sanofi
13.4.5. Johnson & Johnson Services, Inc.
13.4.6. Pfizer, Inc.
13.4.7. Novartis International AG
13.4.8. Eagle Pharmaceuticals, Inc.
13.4.9. GSK Group of Companies
13.4.10. Teva Pharmaceuticals Industries, Ltd.
Methodology
Related Reports
Some other reports from this category!
Our Clients
